{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T22:32:31Z","timestamp":1780439551186,"version":"3.54.1"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T00:00:00Z","timestamp":1722902400000},"content-version":"vor","delay-in-days":218,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Cambridge Biomedical Research Centre and Hoffman La Roche","award":["BE29950"],"award-info":[{"award-number":["BE29950"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Rituximab is used for remission induction and the prevention of relapse in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV). This study evaluated the incidence of safety events and compared time to first serious adverse event (SAE) between a rituximab cohort and a cohort treated with non-rituximab therapies in a real-life setting.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Rituximab surveillance study in vasculitis was a retrospective observational study of patients with AAV who received rituximab (MabThera) or other treatments between 2003 and 2017 at a specialist vasculitis clinic. The primary endpoint was time to first SAE.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>392 patients were enrolled: 247 in the rituximab and 145 in the control cohorts with a total follow up of 2217 person-years (mean study duration 5.7\u2009years). Mean age was 61\u2009years, 77% had granulomatosis with polyangiitis (GPA). There were differences in baseline characteristics (disease duration and prior immunosuppressive use) between groups. 134\/247 patients (54%) in the rituximab and 58\/145 (40%) of controls experienced at least one SAE. Time to first SAE was shorter in the rituximab group (hazard ratio (HR) 1.55, 95% CI 1.07\u20132.26, P\u2009=\u20090.022). Predictors of first SAE were higher vasculitis damage index and the presence of chronic pulmonary or kidney disease. The risk of serious infection was higher in the rituximab group (relative risk (RR) 2.12, 95% CI 1.31\u20133.43).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Over 40% of patients with AAV experienced at least one SAE. Although shorter time to first SAE and higher risk of infection were observed in the rituximab group, baseline imbalances necessitate a careful interpretation of these results.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rap\/rkae090","type":"journal-article","created":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T04:51:46Z","timestamp":1723006306000},"source":"Crossref","is-referenced-by-count":7,"title":["Long-term surveillance study of rituximab originator treated patients with granulomatosis with polyangiitis (GPA)\u00a0or microscopic polyangiitis (MPA)"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0746-8197","authenticated-orcid":false,"given":"Lisa","family":"Uchida","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Cambridge , Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel B","family":"Jones","sequence":"additional","affiliation":[{"name":"Vasculitis and Lupus Clinic, Cambridge University Hospitals NHS Foundation Trust , Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rona M","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Cambridge , Cambridge, UK"},{"name":"Vasculitis and Lupus Clinic, Cambridge University Hospitals NHS Foundation Trust , Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Nodale","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Cambridge , Cambridge, UK"},{"name":"Cambridge Clinical Trials Unit, Cambridge University Hospitals NHS Foundation Trust , Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Bond","sequence":"additional","affiliation":[{"name":"Cambridge Clinical Trials Unit, Cambridge University Hospitals NHS Foundation Trust , Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Loechel","sequence":"additional","affiliation":[{"name":"Vasculitis and Lupus Clinic, Cambridge University Hospitals NHS Foundation Trust , Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"King","sequence":"additional","affiliation":[{"name":"Vasculitis and Lupus Clinic, Cambridge University Hospitals NHS Foundation Trust , Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raashid","family":"Luqmani","sequence":"additional","affiliation":[{"name":"Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford , Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Gray","sequence":"additional","affiliation":[{"name":"Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford , Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Barrett","sequence":"additional","affiliation":[{"name":"Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford , Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1712-0637","authenticated-orcid":false,"given":"David R W","family":"Jayne","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Cambridge , Cambridge, UK"},{"name":"Vasculitis and Lupus Clinic, Cambridge University Hospitals NHS Foundation Trust , Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,8,6]]},"reference":[{"key":"2024082006313057500_rkae090-B1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41572-020-0204-y","article-title":"ANCA-associated vasculitis","volume":"6","author":"Kitching","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"2024082006313057500_rkae090-B2","doi-asserted-by":"crossref","first-page":"488","DOI":"10.7326\/0003-4819-116-6-488","article-title":"Wegener granulomatosis: an analysis of 158 patients","volume":"116","author":"Hoffman","year":"1992","journal-title":"Ann Intern Med"},{"key":"2024082006313057500_rkae090-B3","first-page":"513","author":"Wolff","year":"1974"},{"key":"2024082006313057500_rkae090-B4","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1136\/ard.2005.044420","article-title":"Lack of efficacy of rituximab in Wegener\u2019s granulomatosis with refractory granulomatous manifestations","volume":"65","author":"Aries","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"2024082006313057500_rkae090-B5","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1002\/art.22046","article-title":"Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment","volume":"54","author":"Smith","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2024082006313057500_rkae090-B6","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1002\/art.24637","article-title":"A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis","volume":"60","author":"Jones","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2024082006313057500_rkae090-B7","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N Engl J Med"},{"key":"2024082006313057500_rkae090-B8","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"key":"2024082006313057500_rkae090-B9","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis","volume":"371","author":"Guillevin","year":"2014","journal-title":"N Engl J Med"},{"key":"2024082006313057500_rkae090-B10","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1136\/ard-2022-223559","article-title":"Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial","volume":"82","author":"Smith","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2024082006313057500_rkae090-B11","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/ard-2022-223764","article-title":"EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update","volume":"83","author":"Hellmich","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2024082006313057500_rkae090-B12","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3899\/jrheum.190065","article-title":"Prevalence and risk factors for major infections in patients with antineutrophil cytoplasmic antibody-associated vasculitis: influence on the disease outcome","volume":"47","author":"Garcia-Vives","year":"2020","journal-title":"J Rheumatol"},{"key":"2024082006313057500_rkae090-B13","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1136\/ard.2010.137778","article-title":"Long-term patient survival in ANCA-associated vasculitis","volume":"70","author":"Flossmann","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2024082006313057500_rkae090-B14","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.3899\/jrheum.160909","article-title":"Severe infection in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"44","author":"Mohammad","year":"2017","journal-title":"J Rheumatol"},{"key":"2024082006313057500_rkae090-B15","doi-asserted-by":"crossref","first-page":"671503","DOI":"10.3389\/fimmu.2021.671503","article-title":"Rituximab associated hypogammaglobulinemia in autoimmune disease","volume":"12","author":"Tieu","year":"2021","journal-title":"Front Immunol"},{"key":"2024082006313057500_rkae090-B16","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1136\/annrheumdis-2016-209925","article-title":"Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis","volume":"76","author":"van Daalen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2024082006313057500_rkae090-B17","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1136\/ard.2010.145250","article-title":"Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European Vasculitis Study Group clinical trials","volume":"70","author":"Heijl","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2024082006313057500_rkae090-B18","doi-asserted-by":"crossref","first-page":"404","DOI":"10.3109\/03009742.2016.1138318","article-title":"Late-onset neutropenia after rituximab in ANCA-associated vasculitis","volume":"45","author":"Knight","year":"2016","journal-title":"Scand J Rheumatol"},{"key":"2024082006313057500_rkae090-B19","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1093\/rheumatology\/kex338","article-title":"Cardiovascular events in anti-neutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis of observational studies","volume":"57","author":"Houben","year":"2018","journal-title":"Rheumatology"},{"key":"2024082006313057500_rkae090-B20","doi-asserted-by":"crossref","first-page":"4616","DOI":"10.1093\/rheumatology\/keab057","article-title":"Venous thromboembolism in ANCA-associated vasculitis: a population-based cohort study","volume":"60","author":"Liapi","year":"2021","journal-title":"Rheumatology"},{"key":"2024082006313057500_rkae090-B21","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1093\/rheumatology\/ken035","article-title":"Venous thromboembolism in ANCA-associated vasculitis\u2014incidence and risk factors","volume":"47","author":"Stassen","year":"2008","journal-title":"Rheumatology"},{"key":"2024082006313057500_rkae090-B22","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1136\/ard.2009.109389","article-title":"Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis","volume":"69","author":"Little","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2024082006313057500_rkae090-B23","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1002\/acr.24332","article-title":"Long-term safety of rituximab in granulomatosis with polyangiitis and in microscopic polyangiitis","volume":"73","author":"Merkel","year":"2021","journal-title":"Arthritis Care Res"},{"key":"2024082006313057500_rkae090-B24","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1093\/ndt\/gfaa303","article-title":"Increasing incidence and improved survival in ANCA-associated vasculitis\u2014a Danish nationwide study","volume":"37","author":"Nelveg-Kristensen","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"2024082006313057500_rkae090-B25","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.autrev.2017.11.015","article-title":"Clinical and microbiological characteristics of the infections in patients treated with rituximab for autoimmune and\/or malignant hematological disorders","volume":"17","author":"Tudesq","year":"2018","journal-title":"Autoimmun Rev"},{"key":"2024082006313057500_rkae090-B26","doi-asserted-by":"crossref","first-page":"102505","DOI":"10.1016\/j.autrev.2020.102505","article-title":"Severe infections in patients with anti-neutrophil cytoplasmic antibody-associated vasculitides receiving rituximab: a meta-analysis","volume":"19","author":"Thery-Casari","year":"2020","journal-title":"Autoimmun Rev"},{"key":"2024082006313057500_rkae090-B27","doi-asserted-by":"crossref","first-page":"558","DOI":"10.3899\/jrheum.090856","article-title":"Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials","volume":"37","author":"van Vollenhoven","year":"2010","journal-title":"J Rheumatol"},{"key":"2024082006313057500_rkae090-B28","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/1471-2474-15-178","article-title":"The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease","volume":"15","author":"Marco","year":"2014","journal-title":"BMC Musculoskelet Disord"},{"key":"2024082006313057500_rkae090-B29","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/art.40032","article-title":"Effect of continuous B cell depletion with rituximab on pathogenic autoantibodies and total IgG levels in antineutrophil cytoplasmic antibody\u2013associated vasculitis","volume":"69","author":"Cortazar","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2024082006313057500_rkae090-B30","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1093\/ckj\/sfx014","article-title":"Immunoglobulin levels and infection risk with rituximab induction for anti-neutrophil cytoplasmic antibody-associated vasculitis","volume":"10","author":"Shah","year":"2017","journal-title":"Clin Kidney J"},{"key":"2024082006313057500_rkae090-B31","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaut.2014.11.009","article-title":"Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease","volume":"57","author":"Roberts","year":"2015","journal-title":"J Autoimmun"},{"key":"2024082006313057500_rkae090-B32","doi-asserted-by":"crossref","first-page":"e37626","DOI":"10.1371\/journal.pone.0037626","article-title":"Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides","volume":"7","author":"Venhoff","year":"2012","journal-title":"PLoS One"},{"key":"2024082006313057500_rkae090-B33","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/acr.22757","article-title":"Association of low B cell count and IgG levels with infection, and poor vaccine response with all-cause mortality in an immunosuppressed vasculitis population","volume":"68","author":"David Morgan","year":"2016","journal-title":"Arthritis Care Res"},{"key":"2024082006313057500_rkae090-B34","doi-asserted-by":"crossref","first-page":"4654","DOI":"10.1093\/rheumatology\/keab071","article-title":"Association of venous thromboembolic events with skin, pulmonary and kidney involvement in ANCA-associated vasculitis: a multinational study","volume":"60","author":"Moiseev","year":"2021","journal-title":"Rheumatology"},{"key":"2024082006313057500_rkae090-B35","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1002\/art.39317","article-title":"Incidence of malignancies in patients with antineutrophil cytoplasmic antibody-associated vasculitis diagnosed between 1991 and 2013","volume":"67","author":"Rahmattulla","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2024082006313057500_rkae090-B36","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.jaad.2022.11.044","article-title":"Risk of melanoma and nonmelanoma skin cancer with immunosuppressants, part I: Calcineurin inhibitors, thiopurines, IMDH inhibitors, mTOR inhibitors, and corticosteroids","volume":"88","author":"Kreher","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"2024082006313057500_rkae090-B37","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s13365-018-0615-7","article-title":"Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event","volume":"24","author":"Berger","year":"2018","journal-title":"J Neurovirol"},{"key":"2024082006313057500_rkae090-B38","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1002\/art.40937","article-title":"Predicting severe infection and effects of hypogammaglobulinemia during therapy with rituximab in rheumatic and musculoskeletal diseases","volume":"71","author":"Md Yusof","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2024082006313057500_rkae090-B39","first-page":"795","article-title":"Earliest total vascular damage index scores independently predict all-cause mortality in patients with ANCA-associated vasculitis","volume":"42","author":"Koo","year":"2024","journal-title":"Clin Exp Rheumatol"},{"key":"2024082006313057500_rkae090-B40","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1136\/ard-2022-223401","article-title":"Risk factors for serious infections in ANCA-associated vasculitis","volume":"82","author":"Odler","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2024082006313057500_rkae090-B41","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1136\/annrheumdis-2017-212861","article-title":"Trimethoprim\u2014sulfamethoxazole prophylaxis prevents severe\/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis","volume":"77","author":"Kronbichler","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2024082006313057500_rkae090-B42","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1056\/NEJMoa1803537","article-title":"Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis","volume":"382","author":"Walsh","year":"2020","journal-title":"N Engl J Med"},{"key":"2024082006313057500_rkae090-B43","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1001\/jama.2021.6615","article-title":"Effect of reduced-dose vs high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis: a randomized clinical trial","volume":"325","author":"Furuta","year":"2021","journal-title":"JAMA"}],"container-title":["Rheumatology Advances in Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumap\/advance-article-pdf\/doi\/10.1093\/rap\/rkae090\/58749500\/rkae090.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumap\/article-pdf\/8\/3\/rkae090\/58857054\/rkae090.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumap\/article-pdf\/8\/3\/rkae090\/58857054\/rkae090.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T08:23:33Z","timestamp":1724142213000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumap\/article\/doi\/10.1093\/rap\/rkae090\/7728465"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6,7]]}},"URL":"https:\/\/doi.org\/10.1093\/rap\/rkae090","relation":{},"ISSN":["2514-1775"],"issn-type":[{"value":"2514-1775","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024]]},"published":{"date-parts":[[2024]]},"article-number":"rkae090"}}